The 36-month beta value for ACET is at 1.80. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ACET is 66.22M, and currently, shorts hold a 6.32% of that float. The average trading volume for ACET on October 02, 2024 was 709.46K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ACET) stock’s latest price update
The stock of Adicet Bio Inc (NASDAQ: ACET) has decreased by -1.39 when compared to last closing price of 1.44. Despite this, the company has experienced a 2.16% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-09-30 that REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on September 30, 2024. Four individuals were hired by Adicet in September 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 33,600 shares of Adicet’s common stock with an exercise price of $1.
ACET’s Market Performance
ACET’s stock has risen by 2.16% in the past week, with a monthly drop of -2.74% and a quarterly rise of 29.09%. The volatility ratio for the week is 6.31% while the volatility levels for the last 30 days are 7.35% for Adicet Bio Inc The simple moving average for the last 20 days is -2.81% for ACET stock, with a simple moving average of -23.69% for the last 200 days.
Analysts’ Opinion of ACET
Many brokerage firms have already submitted their reports for ACET stocks, with Guggenheim repeating the rating for ACET by listing it as a “Buy.” The predicted price for ACET in the upcoming period, according to Guggenheim is $7 based on the research report published on September 30, 2024 of the current year 2024.
ACET Trading at -2.37% from the 50-Day Moving Average
After a stumble in the market that brought ACET to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.33% of loss for the given period.
Volatility was left at 7.35%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares sank -4.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.65% upper at present.
During the last 5 trading sessions, ACET rose by +2.16%, which changed the moving average for the period of 200-days by -6.58% in comparison to the 20-day moving average, which settled at $1.4575. In addition, Adicet Bio Inc saw -24.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACET starting from Kauffman Michael, who sale 5,900 shares at the price of $1.43 back on Jun 05 ’24. After this action, Kauffman Michael now owns 5,900 shares of Adicet Bio Inc, valued at $8,437 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Adicet Bio Inc, purchase 3,125,000 shares at $2.40 during a trade that took place back on Jan 25 ’24, which means that ORBIMED ADVISORS LLC is holding 7,526,359 shares at $7,500,000 based on the most recent closing price.
Stock Fundamentals for ACET
Current profitability levels for the company are sitting at:
- -11.44 for the present operating margin
- 0.43 for the gross margin
The net margin for Adicet Bio Inc stands at -10.65. The total capital return value is set at -0.59. Equity return is now at value -57.91, with -50.25 for asset returns.
Based on Adicet Bio Inc (ACET), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -4.76. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 3207.57.
Currently, EBITDA for the company is -126.48 million with net debt to EBITDA at 1.7. When we switch over and look at the enterprise to sales, we see a ratio of -6.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.75.
Conclusion
In conclusion, Adicet Bio Inc (ACET) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
